Prévisions du marché des maladies cardiométaboliques en Amérique du Nord jusqu’en 2028 – Impact du COVID-19 et analyse régionale par type (maladie cardiovasculaire (MCV), diabète de type 2, hypertension et obésité), traitement (inhibiteurs de l’ECA, diurétiques, glucophage et autres), posologie ( comprimé et injection), voie d\'administration (orale et intraveineuse), utilisateurs finaux (établissements hospitaliers, cliniques et de soins à domicile) et canal de distribution (pharmacie hospitalière, pharmacie de détail et pharmacie en ligne)
Introduction au marché
La maladie cardiométabolique est caractérisée par un groupe d\'anomalies et de symptômes qui soulèvent le risque que les individus développent une maladie cardiovasculaire. L\'hypertension, l\'obésité, la résistance à l\'insuline, la dyslipidémie, un mauvais profil de cholestérol (LDL) et une tolérance au glucose sont quelques-uns des symptômes. Les personnes souffrant du syndrome cardiométabolique sont sujettes à plusieurs autres maladies potentiellement mortelles telles que le diabète de type 2, les accidents vasculaires cérébraux, les maladies coronariennes (MAC), les maladies cardiovasculaires (MCV) et bien d\'autres.
De plus, la prévalence croissante des maladies cardiométaboliques devrait soutenir la croissance du marché au cours de la période de prévision. Cependant, le sous-diagnostic des maladies cardiovasculaires dans les pays à revenu faible et intermédiaire (PRFI) limite la croissance du marché des maladies cardiométaboliques en Amérique du Nord.
L\'impact du COVID-19 continue de s\'accentuer. , et le fardeau qui en résulte pour les systèmes médicaux a perturbé les économies, les systèmes de santé et les essais cliniques en cours. La pandémie de COVID-19 a également déclenché l’apparition ou aggravé des maladies cardiovasculaires. En outre, la COVID-19 entraîne de graves problèmes de santé mentale, et le lien entre la dépression et les maladies cardiovasculaires est signalé depuis longtemps. Selon la Cleveland Clinic, environ 15 % des patients atteints de maladies cardiovasculaires et jusqu\'à 20 % des patients ayant subi un pontage aorto-coronarien souffrent de dépression majeure. Même une dépression légère, comme une humeur dépressive, peut augmenter le risque relatif de maladie coronarienne. Les mesures restrictives prises pendant la pandémie de COVID-19 pourraient avoir accru la dépression chez les patients atteints de maladies cardiovasculaires. En outre, de nombreuses sociétés ont signalé une baisse des ventes de médicaments contre les maladies cardiovasculaires et le diabète aux États-Unis. Par exemple, au quatrième trimestre 2020, les ventes mondiales de Sanofi dans le domaine du diabète ont diminué de 8,4 % en raison d\'une baisse continue du prix moyen de la glargine aux États-Unis et de l\'impact de l\'environnement COVID-19. En outre, les ventes de produits cardiovasculaires ont diminué de 7,1 %, en partie à cause de l\'environnement lié à la COVID-19.
Aperçu du marché et Dynamics
Le marché nord-américain des maladies cardiométaboliques devrait atteindre 43 583,6 millions de dollars américains d\'ici 2028, contre 32 912,1 millions de dollars américains en 2021 ; il devrait croître à un TCAC de 4,1 % de 2021 à 2028. L’intégration de l’IA offre en outre des opportunités lucratives pour la croissance du marché mondial des maladies cardiométaboliques et devrait continuer à soutenir ce marché au cours de la période de prévision. En juin 2021, l\'ACC et GE Healthcare ont collaboré grâce au soutien et à la participation au Consortium d\'innovation en santé appliquée (AHIC) de l\'ACC pour élaborer une feuille de route pour l\'IA et la technologie numérique en cardiologie et développer de nouvelles stratégies pour améliorer les résultats en matière de santé.
Segments clés du marché
En termes de type, le segment des maladies cardiovasculaires représentait pour la plus grande part du marché des maladies cardiométaboliques en Amérique du Nord en 2020. En termes de traitement, le segment des inhibiteurs de l\'ECA représentait la plus grande part du marché des maladies cardiométaboliques en Amérique du Nord en 2020. En termes de dosage, le segment des comprimés représentait la plus grande part du marché des maladies cardiométaboliques en Amérique du Nord en 2020. part du marché des maladies cardiométaboliques en Amérique du Nord en 2020. En termes de voie d’administration, le segment oral représentait la plus grande part du marché des maladies cardiométaboliques en Amérique du Nord en 2020. En termes d’utilisateur final, le segment hospitalier représentait la plus grande part du marché des maladies cardiométaboliques en Amérique du Nord en 2020. De plus, sur la base du canal de distribution, le segment de la pharmacie hospitalière détenait la plus grande part de marché en 2020.
Principales sources et sociétés répertoriées
Quelques sources primaires et secondaires majeures citées pour la préparation de ce rapport sur les maladies cardiométaboliques Le marché nord-américain comprend, entre autres, les sites Web d\'entreprises, les rapports annuels, les rapports financiers, les documents gouvernementaux nationaux et les bases de données statistiques. Les principales sociétés répertoriées dans le rapport sont Eli Lilly and Company., Bayer AG, Arrowhead Pharmaceuticals, Inc., Novartis AG, Boehringer Ingelheim International Gmbh, Novo Nordisk A/S, AstraZeneca, Alnylam Pharmaceuticals, Inc., Cardax, Inc. et Kowa Company, Ltd.
Rapport sur les raisons d\'acheter
- Comprendre le paysage du marché des maladies cardiométaboliques en Amérique du Nord et identifier les segments de marché susceptibles de garantir un fort rendement
- Comprendre le paysage du marché en constante évolution et garder une longueur d\'avance sur la concurrence
- Planifier efficacement les fusions, acquisitions et accords de partenariat sur le marché des maladies cardiométaboliques en Amérique du Nord en identifiant les segments avec les ventes probables les plus prometteuses
- Prendre des décisions commerciales éclairées à partir d\'une analyse perspicace et complète des performances du marché de divers segments
- Pour obtenir des prévisions de revenus du marché des maladies cardiométaboliques en Amérique du Nord en fonction de divers segments pour la période 2021-2028
SEGMENTATION DU MARCHÉ DES MALADIES CARDIOMÉTABOLIQUES EN AMÉRIQUE DU NORD
Par type
- Maladie cardiovasculaire (MCV)
- Diabète de type 2
- Hypertension
- Obésité
Par traitement
- Inhibiteurs de l\'ECA
- Diurétiques
- Glucophage
- Autres
Par dosage
- Comprimé
- Injection
Par voie d\'administration
- Oral
- Intraveineuse
Par les utilisateurs finaux
- Hôpital
- Clinique
- Établissement de soins à domicile
- Pharmacie hospitalière
- Pharmacie de détail
- Pharmacie en ligne
Par pays
- Amérique du Nord
- États-Unis
- Canada
- Mexique
Entreprises mentionnées
- Eli Lilly et compagnie.
- Bayer AG
- Arrowhead Pharmaceuticals, Inc
- Novartis AG ;
- Boehringer Ingelheim International Gmbh
- Novo Nordisk A/S
- AstraZeneca
- Alnylam Pharmaceuticals, Inc.
- Cardax, Inc.
- Kowa Company, Ltd.
TABLE OF CONTENTS
1. Introduction
1.1 Scope of the Study
1.2 The Insight Partners Research Report Guidance
1.3 Market Segmentation
1.3.7 North America Cardiometabolic Diseases market – By Country
2. North America Cardiometabolic Diseases Market – Key Takeaways
3. Research Methodology
3.1 Coverage
3.2 Secondary Research
3.3 Primary Research
4. North America Cardiometabolic Diseases Market – Market Landscape
4.1 Overview
4.2 PEST Analysis
4.3 Expert Opinions
5. North America Cardiometabolic Diseases Market – Key Market Dynamics
5.1 Market Drivers
5.1.1 Increasing Prevalence of Cardiometabolic Diseases
5.1.2 Innovation in Cardiometabolic Diseases Therapeutics
5.2 Market Restraints
5.2.1 Underdiagnosis of CVDs in Low- and Middle-Income Countries (LMICs)
5.3 Market Opportunities
5.3.1 Technological Advancements in CMD Diagnosis
5.4 Future Trends
5.4.1 Personalized Treatment for CMDs
5.5 Impact Analysis
6. North America Cardiometabolic Diseases Market – Regional Analysis
6.1 North America Cardiometabolic Diseases Market Revenue Forecast And Analysis
7. North America Cardiometabolic Diseases Market Analysis – By Type
7.1 Overview
7.2 Cardiometabolic Diseases Market Revenue Share, by Type (2020 and 2028)
7.3 Cardiovascular Disease (CVD)
7.3.1 Overview
7.3.2 Cardiovascular Disease (CVD): Cardiometabolic Diseases Market Revenue and Forecast to 2028 (US$ Mn)
7.4 Hypertension
7.4.1 Overview
7.4.2 Hypertension: Cardiometabolic Diseases Market Revenue and Forecast to 2028 (US$ Mn)
7.5 Type 2 Diabetes
7.5.1 Overview
7.5.2 Type 2 Diabetes: Cardiometabolic Diseases Market Revenue and Forecast to 2028 (US$ Mn)
7.6 Obesity
7.6.1 Overview
7.6.2 Obesity: Cardiometabolic Diseases Market Revenue and Forecast to 2028 (US$ Mn)
8. North America Cardiometabolic Diseases Market Analysis – By Treatment
8.1 Overview
8.2 Cardiometabolic Diseases Market Revenue Share, by Treatment (2020 and 2028)
8.3 ACE inhibitors
8.3.1 Overview
8.3.2 ACE: Cardiometabolic Diseases Inhibitors Market Revenue and Forecast to 2028 (US$ Mn)
8.4 Diuretics
8.4.1 Overview
8.4.2 Diuretics: Cardiometabolic Diseases Market Revenue and Forecast to 2028 (US$ Mn)
8.5 Glucophage
8.5.1 Overview
8.5.2 Glucophage: Cardiometabolic Diseases Market Revenue and Forecast to 2028 (US$ Mn)
8.6 Others
8.6.1 Overview
8.6.2 Others: Cardiometabolic Diseases Market Revenue and Forecast to 2028 (US$ Mn)
9. North America Cardiometabolic Diseases Market Analysis – By Dosage
9.1 Overview
9.2 Cardiometabolic Diseases Market Revenue Share, by Dosage (2020 and 2028)
9.3 Tablet
9.3.1 Overview
9.3.2 Tablet: Cardiometabolic Diseases Market Revenue and Forecast to 2028 (US$ Mn)
9.4 Injection
9.4.1 Overview
9.4.2 Injection: Cardiometabolic Diseases Market Revenue and Forecast to 2028 (US$ Mn)
10. North America Cardiometabolic Diseases Market Analysis – By Route of Administration
10.1 Overview
10.2 Cardiometabolic Diseases Market Share by Route of Administration 2021 & 2028 (%)
10.3 Oral
10.3.1 Overview
10.3.2 Oral Market Revenue and Forecast to 2028 (US$ Mn)
10.4 Intravenous
10.4.1 Overview
10.4.2 Intravenous Market Revenue and Forecast to 2028 (US$ Mn)
11. North America Cardiometabolic Diseases Market Analysis – By End User
11.1 Overview
11.2 Cardiometabolic Diseases Market Share by End Users 2020 & 2028 (%)
11.3 Clinic
11.3.1 Overview
11.3.2 Clinic Market Revenue and Forecast to 2028 (US$ Mn)
11.4 Hospital
11.4.1 Overview
11.4.2 Hospital Market Revenue and Forecast to 2028 (US$ Mn)
11.5 Homecare Settings
11.5.1 Overview
11.5.2 Homecare Settings Market Revenue and Forecast to 2028 (US$ Mn)
12. North America Cardiometabolic Diseases Market Analysis – By Distribution Channel
12.1 Overview
12.2 Cardiometabolic Diseases Market Share by Distribution Channel 2020 & 2028 (%)
12.3 Hospital Pharmacy
12.3.1 Overview
12.3.2 Hospital Pharmacy Market Revenue and Forecast to 2028 (US$ Mn)
12.4 Retail Pharmacy
12.4.1 Overview
12.4.2 Retail Pharmacy Market Revenue and Forecast to 2028 (US$ Mn)
12.5 Online Pharmacy
12.5.1 Overview
12.5.2 Online Pharmacy Market Revenue and Forecast to 2028 (US$ Mn)
13. North America Cardiometabolic Diseases Market – Geographic Analysis
13.1 North America: Cardiometabolic Diseases Market
13.1.1 Overview
13.1.2 North America: Cardiometabolic Diseases Market - Revenue and Forecast to 2028 (USD Million)
13.1.3 North America Cardiometabolic Diseases Market, by Type – Revenue and Forecast to 2028 (USD Million)
13.1.4 North America Cardiometabolic Diseases Market, by Treatment – Revenue and Forecast to 2028 (USD Million)
13.1.5 North America Cardiometabolic Diseases Market, by Dosage – Revenue and Forecast to 2028 (USD Million)
13.1.6 North America Cardiometabolic Diseases Market, by Route of Administration – Revenue and Forecast to 2028 (USD Million)
13.1.7 North America Cardiometabolic Diseases Market, by End User – Revenue and Forecast to 2028 (USD Million)
13.1.8 North America Cardiometabolic Diseases Market, by Distribution Channel– Revenue and Forecast to 2028 (USD Million)
13.1.9 North America: Cardiometabolic Diseases Market, by Country, 2021 & 2028 (%)
13.1.9.1 US: Cardiometabolic Diseases Market – Revenue and Forecast to 2028 (USD Million)
13.1.9.1.1 US: Cardiometabolic Diseases Market – Revenue and Forecast to 2028 (USD Million)
13.1.9.1.2 US Cardiometabolic Diseases Market, by Type – Revenue and Forecast to 2028 (USD Million)
13.1.9.1.3 US: Cardiometabolic Diseases Market, by Treatment – Revenue and Forecast to 2028 (USD Million)
13.1.9.1.4 US: Cardiometabolic Diseases Market, by Dosage – Revenue and Forecast to 2028 (USD Million)
13.1.9.1.5 US: Cardiometabolic Diseases Market, by Route of Administration– Revenue and Forecast to 2028 (USD Million)
13.1.9.1.6 US: Cardiometabolic Diseases Market, by End User – Revenue and Forecast to 2028 (USD Million)
13.1.9.1.7 US: Cardiometabolic Diseases Market, by Distribution Channel – Revenue and Forecast to 2028 (USD Million)
13.1.9.2 Canada: Cardiometabolic Diseases Market – Revenue and Forecast to 2028 (USD Million)
13.1.9.2.1 Canada: Cardiometabolic Diseases Market – Revenue and Forecast to 2028 (USD Million)
13.1.9.2.2 Canada: Cardiometabolic Diseases Market, by Type – Revenue and Forecast to 2028 (USD Million)
13.1.9.2.3 Canada: Cardiometabolic Diseases Market, by Treatment – Revenue and Forecast to 2028 (USD Million)
13.1.9.2.4 Canada: Cardiometabolic Diseases Market, by Dosage – Revenue and Forecast to 2028 (USD Million)
13.1.9.2.5 Canada: Cardiometabolic Diseases Market, by Route of Administration– Revenue and Forecast to 2028 (USD Million)
13.1.9.2.6 Canada: Cardiometabolic Diseases Market, by End User – Revenue and Forecast to 2028 (USD Million)
13.1.9.2.7 Canada: Cardiometabolic Diseases Market, by Distribution Channel– Revenue and Forecast to 2028 (USD Million)
13.1.9.3 Mexico: Cardiometabolic Diseases Market – Revenue and Forecast to 2028 (USD Million)
13.1.9.3.1 Mexico: Cardiometabolic Diseases Market – Revenue and Forecast to 2028 (USD Million)
13.1.9.3.2 Mexico: Cardiometabolic Diseases Market, by Type – Revenue and Forecast to 2028 (USD Million)
13.1.9.3.3 Mexico: Cardiometabolic Diseases Market, by Treatment – Revenue and Forecast to 2028 (USD Million)
13.1.9.3.4 Mexico: Cardiometabolic Diseases Market, by Dosage – Revenue and Forecast to 2028 (USD Million)
13.1.9.3.5 Mexico: Cardiometabolic Diseases Market, by Route of Administration– Revenue and Forecast to 2028 (USD Million)
13.1.9.3.6 Mexico: Cardiometabolic Diseases Market, by End User – Revenue and Forecast to 2028 (USD Million)
13.1.9.3.7 Mexico: Cardiometabolic Diseases Market, by Distribution Channel – Revenue and Forecast to 2028 (USD Million)
14. Impact of COVID-19 Pandemic on North America Cardiometabolic Diseases Market
14.1 North America: Impact Assessment of COVID-19 Pandemic
15. North America Cardiometabolic Diseases Market – Industry Landscape
15.1 Overview
15.2 Growth Strategies in the Cardiometabolic Diseases Market (%)
15.3 Organic Developments
15.3.1 Overview
15.4 Inorganic Developments
15.4.1 Overview
16. Company Profiles
16.1 Eli Lilly and Company.
16.1.1 Key Facts
16.1.2 Business Description
16.1.3 Products and Services
16.1.4 Financial Overview
16.1.5 SWOT Analysis
16.1.6 Key Developments
16.2 Bayer AG
16.2.1 Key Facts
16.2.2 Business Description
16.2.3 Products and Services
16.2.4 Financial Overview
16.2.5 SWOT Analysis
16.2.6 Key Developments
16.3 Arrowhead Pharmaceuticals, Inc
16.3.1 Key Facts
16.3.2 Business Description
16.3.3 Products and Services
16.3.4 Financial Overview
16.3.5 SWOT Analysis
16.3.6 Key Developments
16.4 Novartis AG
16.4.1 Key Facts
16.4.2 Business Description
16.4.3 Products and Services
16.4.4 Financial Overview
16.4.5 SWOT Analysis
16.4.6 Key Developments
16.5 Boehringer Ingelheim International GmbH
16.5.1 Key Facts
16.5.2 Business Description
16.5.3 Products and Services
16.5.4 Financial Overview
16.5.5 SWOT Analysis
16.5.6 Key Developments
16.6 Novo Nordisk A/S
16.6.1 Key Facts
16.6.2 Business Description
16.6.3 Products and Services
16.6.4 Financial Overview
16.6.5 SWOT Analysis
16.6.6 Key Developments
16.7 AstraZeneca
16.7.1 Key Facts
16.7.2 Business Description
16.7.3 Products and Services
16.7.4 Financial Overview
16.7.5 SWOT Analysis
16.7.6 Key Developments
16.8 Alnylam Pharmaceuticals, Inc.
16.8.1 Key Facts
16.8.2 Business Description
16.8.3 Products and Services
16.8.4 Financial Overview
16.8.5 SWOT Analysis
16.8.6 Key Developments
16.9 Cardax, Inc.
16.9.1 Key Facts
16.9.2 Business Description
16.9.3 Products and Services
16.9.4 Financial Overview
16.9.5 SWOT Analysis
16.9.6 Key Developments
16.10 Kowa Company, Ltd.
16.10.1 Key Facts
16.10.2 Business Description
16.10.3 Products and Services
16.10.4 Financial Overview
16.10.5 SWOT Analysis
16.10.6 Key Developments
17. Appendix
17.1 About The Insight Partners
17.2 Glossary of Terms
LIST OF TABLES
Table 1. North America Cardiometabolic Diseases Market, by Type – Revenue and Forecast to 2028 (USD Million)
Table 2. North America Cardiometabolic Diseases Market, by Treatment - Revenue and Forecast to 2028 (USD Million)
Table 3. North America Cardiometabolic Diseases Market, by Dosage - Revenue and Forecast to 2028 (USD Million)
Table 4. North America Cardiometabolic Diseases Market, by Route of Administration - Revenue and Forecast to 2028 (USD Million)
Table 5. North America Cardiometabolic Diseases Market, by End User- Revenue and Forecast to 2028 (USD Million)
Table 6. North America Cardiometabolic Diseases Market, by Distribution Channel- Revenue and Forecast to 2028 (USD Million)
Table 7. US Cardiometabolic Diseases Market, by Type – Revenue and Forecast to 2028 (USD Million)
Table 8. US Cardiometabolic Diseases Market, by Treatment - Revenue and Forecast to 2028 (USD Million)
Table 9. US Cardiometabolic Diseases Market, by Dosage - Revenue and Forecast to 2028 (USD Million)
Table 10. US Cardiometabolic Diseases Market, by Route of Administration- Revenue and Forecast to 2028 (USD Million)
Table 11. US Cardiometabolic Diseases Market, by End User- Revenue and Forecast to 2028 (USD Million)
Table 12. US Cardiometabolic Diseases Market, by Distribution Channel - Revenue and Forecast to 2028 (USD Million)
Table 13. Canada: Cardiometabolic Diseases Market, by Type -Revenue and Forecast to 2028 (USD Million)
Table 14. Canada: Cardiometabolic Diseases Market, by Treatment – Revenue and Forecast to 2028 (USD Million)
Table 15. Canada: Cardiometabolic Diseases Market, by Dosage – Revenue and Forecast to 2028 (USD Million)
Table 16. Canada: Cardiometabolic Diseases Market, by Route of Administration– Revenue and Forecast to 2028 (USD Million)
Table 17. Canada: Cardiometabolic Diseases Market, by End User – Revenue and Forecast to 2028 (USD Million)
Table 18. Canada: Cardiometabolic Diseases Market, by Distribution Channel– Revenue and Forecast to 2028 (USD Million)
Table 19. Mexico Cardiometabolic Diseases Market, by Type -Revenue and Forecast to 2028 (USD Million)
Table 20. Mexico Cardiometabolic Diseases Market, by Treatment – Revenue and Forecast to 2028 (USD Million)
Table 21. Mexico Cardiometabolic Diseases Market, by Dosage – Revenue and Forecast to 2028 (USD Million)
Table 22. Mexico Cardiometabolic Diseases Market, by Route of Administration– Revenue and Forecast to 2028 (USD Million)
Table 23. Mexico Cardiometabolic Diseases Market, by End User – Revenue and Forecast to 2028 (USD Million)
Table 24. Mexico Cardiometabolic Diseases Market, by Distribution Channel – Revenue and Forecast to 2028 (USD Million)
Table 25. Organic Developments in the Cardiometabolic Diseases Market
Table 26. Inorganic Developments in the Cardiometabolic Diseases Market
Table 27. Glossary of Terms, North America Cardiometabolic Diseases Market
LIST OF FIGURES
Figure 1. North America Cardiometabolic Diseases Market Segmentation
Figure 2. North America Cardiometabolic Diseases Market Overview
Figure 3. Cardiovascular Disease (CVD) Segment Held Largest Share Type of North America Cardiometabolic Diseases Market
Figure 4. North America Cardiometabolic Diseases Market – Leading Country Markets (US$ Million)
Figure 5. North America Cardiometabolic Diseases Market, Industry Landscape
Figure 6. North America PEST Analysis
Figure 7. North America Cardiometabolic Diseases Market Impact Analysis of Drivers and Restraints
Figure 8. North America Cardiometabolic Diseases Market – Revenue Forecast And Analysis – 2020- 2028
Figure 9. Cardiometabolic Diseases Market Revenue Share, by Type (2020 and 2028)
Figure 10. Cardiovascular Disease (CVD): Cardiometabolic Diseases Market Revenue and Forecasts to 2028 (US$ Mn)
Figure 11. Hypertension: Cardiometabolic Diseases Market Revenue and Forecasts to 2028 (US$ Mn)
Figure 12. Type 2 Diabetes: Cardiometabolic Diseases Market Revenue and Forecasts to 2028 (US$ Mn)
Figure 13. Obesity: Cardiometabolic Diseases Market Revenue and Forecasts to 2028 (US$ Mn)
Figure 14. Cardiometabolic Diseases Market Revenue Share, by Treatment (2020 and 2028)
Figure 15. ACE inhibitors: Cardiometabolic Diseases Market Revenue and Forecasts to 2028 (US$ Mn)
Figure 16. Diuretics: Cardiometabolic Diseases Market Revenue and Forecasts to 2028 (US$ Mn)
Figure 17. Glucophage: Cardiometabolic Diseases Market Revenue and Forecasts to 2028 (US$ Mn)
Figure 18. Others: Cardiometabolic Diseases Market Revenue and Forecasts to 2028 (US$ Mn)
Figure 19. Cardiometabolic Diseases Market Revenue Share, by Dosage (2020 and 2028)
Figure 20. Tablet: Cardiometabolic Diseases Market Revenue and Forecasts to 2028 (US$ Mn)
Figure 21. Injection: Cardiometabolic Diseases Market Revenue and Forecasts to 2028 (US$ Mn)
Figure 22. Cardiometabolic Diseases Market Share by Route of Administration 2021 & 2028 (%)
Figure 23. Oral Market Revenue and Forecasts to 2028 (US$ Mn)
Figure 24. Intravenous Market Revenue and Forecasts to 2028 (US$ Mn)
Figure 25. Cardiometabolic Diseases Market Share by End Users 2020 & 2028 (%)
Figure 26. Clinic Market Revenue and Forecasts to 2028 (US$ Mn)
Figure 27. Hospital Market Revenue and Forecasts to 2028 (US$ Mn)
Figure 28. Homecare Settings Market Revenue and Forecasts to 2028 (US$ Mn)
Figure 29. Cardiometabolic Diseases Market Share by Distribution Channel 2020 & 2028 (%)
Figure 30. Hospital Pharmacy Market Revenue and Forecasts to 2028 (US$ Mn)
Figure 31. Retail Pharmacy Market Revenue and Forecasts to 2028 (US$ Mn)
Figure 32. Online Pharmacy Market Revenue and Forecasts to 2028 (US$ Mn)
Figure 33. North America: Cardiometabolic Diseases Market, by Key Country – Revenue (2021) (USD Million)
Figure 34. North America Cardiometabolic Diseases Market Revenue and Forecast to 2028 (USD Million)
Figure 35. North America: Cardiometabolic Diseases Market, by Country, 2021 & 2028 (%)
Figure 36. US: Cardiometabolic Diseases Market – Revenue and Forecast to 2028 (USD Million)
Figure 37. Canada: Cardiometabolic Diseases Market – Revenue and Forecast to 2028 (USD Million)
Figure 38. Mexico: Cardiometabolic Diseases Market – Revenue and Forecast to 2028 (USD Million)
Figure 39. Impact of COVID-19 Pandemic on North America Cardiometabolic Diseases Market
Figure 40. Growth Strategies in the Cardiometabolic Diseases Market (%)
S
- Eli Lilly and Company.
- Bayer AG
- Arrowhead Pharmaceuticals, Inc
- Novartis AG
- Boehringer Ingelheim International Gmbh
- Novo Nordisk A/S
- AstraZeneca
- Alnylam Pharmaceuticals, Inc.
- Cardax, Inc.
- Kowa Company, Ltd.
- Save and reduce time carrying out entry-level research by identifying the growth, size, leading players, and segments in the North America cardiometabolic diseases market.
- Highlights key business priorities in order to assist companies to realign their business strategies.
- The key findings and recommendations highlight crucial progressive industry trends in the North America cardiometabolic diseases market, thereby allowing players across the value chain to develop effective long-term strategies.
- Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.
- Scrutinize in-depth global market trends and outlook coupled with the factors driving the market, as well as those hindering it.
- Enhance the decision-making process by understanding the strategies that underpin security interest with respect to client products, segmentation, pricing and distribution.